<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266135</url>
  </required_header>
  <id_info>
    <org_study_id>CQAX576A2203</org_study_id>
    <secondary_id>2010-020688-18</secondary_id>
    <nct_id>NCT01266135</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled, Multiple-dose, Exploratory Proof of Concept Study to Assess the Safety, Tolerability, Efficacy, Pharmacodynamic (PD) and Pharmacokinetics of QAX576 in Patients With Rapidly Progressive IPF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability, pharmacokinetics and efficacy of&#xD;
      QAX576 in patients with idiopathic pulmonary fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety, tolerability, and effect on lung function of multiple intravenous doses of QAX576 in patients with IPF</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in forced vital capacity (FVC) at 52 weeks as compared to baseline</measure>
    <time_frame>1 year</time_frame>
    <description>Measure: FVC was measured using a spirometer according to American Thoracic Society / European Respiratory Society guidelines at screening and week 52 of the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of QAX576.</measure>
    <time_frame>1 year</time_frame>
    <description>Measure safety and tolerability as assessed by reported AEs and effects on routine laboratory evaluations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of multiple intravenous doses of QAX576 on measures of clinical efficacy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetics of of QAX576 by measuring concentrations of QAX576 in blood</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical worsening:</measure>
    <time_frame>1 year</time_frame>
    <description>Measure: Time to clinical worsening defined as fall in FVC or Diffusing Capacity of the lung for Carbon Monoxide (DLco), lung transplant or lung disease (IPF)-related death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbation of IPF</measure>
    <time_frame>1 year</time_frame>
    <description>Measure: Incidence of exacerbation of IPF during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of fibrosis</measure>
    <time_frame>1 year</time_frame>
    <description>Measure progression of fibrosis in the lungs as measured by Quantitative High Resolution Computerized Tomography (HRCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of QAX576</measure>
    <time_frame>1 year</time_frame>
    <description>Measure concentrations of QAX576 and its metabolites in blood throughout the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Arm 1: QAX576 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QAX576</intervention_name>
    <description>QAX576 10 mg/kg intravenous infusion</description>
    <arm_group_label>Arm 1: QAX576 10 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to QAX576 intravenous infusion</description>
    <arm_group_label>Arm 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Diagnosis of Idiopathic Pulmonary Fibrosis (IPF), based on an appropriate clinical&#xD;
             definition of IPF as detailed in the ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary&#xD;
             Fibrosis: Evidence-based Guidelines for Diagnosis and Management Diagnosis must be&#xD;
             confirmed by a diagnostic HRCT or surgical lung biopsy.&#xD;
&#xD;
          -  A 6-minute walk test (6MWT) distance â‰¥50 meters at Screening (use of supplemental&#xD;
             oxygen allowed).&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Smokers (use of tobacco products in the previous 3 months). Urine cotinine levels will&#xD;
             be measured during screening for all subjects. Smokers will be defined as any subject&#xD;
             who reports tobacco use or has a urine cotinine levels in the range defined as&#xD;
             'smokers' per the local lab.&#xD;
&#xD;
          -  Lung residual volume &gt; 120% predicted at Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SW3 6PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=11844</url>
    <description>Results for CQAX576A2203 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>December 17, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <disposition_first_submitted>August 20, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 20, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 28, 2020</disposition_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interstitial Lung Disease</keyword>
  <keyword>Usual Interstitial Pneumonia</keyword>
  <keyword>Fibrosis,</keyword>
  <keyword>Pulmonary Fibrosis,</keyword>
  <keyword>Respiratory Disease,</keyword>
  <keyword>Interstitial Lung Disease,</keyword>
  <keyword>Biological Therapy,</keyword>
  <keyword>Therapeutic Uses,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

